Expression of microRNA-129-2-3p and microRNA-935 in plasma and brain tissue of human refractory epilepsy

Sun, Yuqiang; Wang, Xiaofeng; Wang, Zeyang; Zhang, Yuanyang; Che, Ningwei; Luo, Xiadong; Tan, Zeshi; Sun, Xu; Li, Xinyu; Yang, Kang; Wang, Guanyu; Luan, Lan; Liu, Yaoling; Zheng, Xiao; Wei, Minghai; Cheng, Huakun; Yin, Jian

doi:10.1016/j.eplepsyres.2016.09.016

Cited by 33 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The design of most of the molecular, electrophysiologic, or MRI bio-marker studies performed in epilepsy populations indicates that the objective has been to discover sensitive and specific biomarkers differentiating the epilepsy population from controls (Table 3). These studies report plasma/serum/CSF miRNA and protein biomarkers, plasma exosome miRNA biomarkers, cortical brain tissue miRNA biomarkers, brain diffusion tensor imaging/diffusion-weighted imaging-MRI biomarkers, and electrophysiologic biomarkers that differentiate patients with epilepsy (Wang et al, 2015b;Wang et al, 2016aWang et al, , 2016b, temporal lobe epilepsy (TLE) (Raoof et al, 2017), medial TLE (mTLE) (Avansini et al, 2017;Liu et al, 2016), mTLE with hippocampal sclerosis (Yan et al, 2017), idiopathic generalized epilepsy (Won et al, 2017), drugrefractory epilepsy (An et al, 2016;Wang et al, 2015a), drug-resistant focal epilepsy (Pollard et al, 2012), drug-refractory TLE (Walker et al, 2017), or focal cortical dysplasia with refractory TLE (Sun et al, 2016b;Wang et al, 2015) from controls ( Table 3). Many of these diagnostic epilepsy biomarkers have an AUC > 0.800, suggesting acceptable sensitivity and specificity to make an epilepsy diagnosis without evidence of the occurrence of a seizure.…”

Section: Diagnostic Biomarkers For Epilepsy-mentioning

confidence: 99%

Epilepsy biomarkers – Toward etiology and pathology specificity

Pitkänen

Ndode-Ekane

Lapinlampi

et al. 2019

Neurobiology of Disease

145

131

View full text Add to dashboard Cite

A biomarker is a characteristic that is measured as an indicator of normal biologic processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities include molecular, histologic, radiographic, or physiologic characteristics. In 2015, the FDA-NIH Joint Leadership Council developed the BEST Resource (Biomarkers, EndpointS, and other Tools) to improve the understanding and use of biomarker terminology in biomedical research, clinical practice, and medical product development. The BEST biomarker categories include: (a) susceptibility/risk biomarkers, (b) diagnostic biomarkers, (c) monitoring biomarkers, (d) prognostic biomarkers, (e) predictive biomarkers, (f) pharmacodynamic/response biomarkers, and (g) safety biomarkers. Here we review 30 epilepsy biomarker studies that have identified (a) diagnostic biomarkers for epilepsy, epileptogenesis, epileptogenicity, drug-refractoriness, and status epilepticus - some of the epileptogenesis and epileptogenicity biomarkers can also be considered prognostic biomarkers for the development of epilepsy in subjects with a given brain insult, (b) predictive biomarkers for epilepsy surgery outcome, and (c) a response biomarker for therapy outcome. The biomarker modalities include plasma/serum/exosomal and cerebrospinal fluid molecular biomarkers, brain tissue molecular biomarkers, imaging biomarkers, electrophysiologic biomarkers, and behavioral/cognitive biomarkers. Both single and combinatory biomarkers have been described. Most of the reviewed biomarkers have an area under the curve >0.800 in receiver operating characteristics analysis, suggesting high sensitivity and specificity. As discussed in this review, we are in the early phase of the learning curve in epilepsy biomarker discovery. Many of the seven biomarker categories lack epilepsy-related biomarkers. There is a need for epilepsy biomarker discovery using proper, statistically powered study designs with validation cohorts, and the development and use of novel analytical methods. A strategic roadmap to discuss the research priorities in epilepsy biomarker discovery, regulatory issues, and optimization of the use of resources, similar to those devised in the cancer and Alzheimer's disease research areas, is also needed.

show abstract

Section: Diagnostic Biomarkers For Epilepsy-mentioning

confidence: 99%

Epilepsy biomarkers – Toward etiology and pathology specificity

Pitkänen

Ndode-Ekane

Lapinlampi

et al. 2019

Neurobiology of Disease

145

131

View full text Add to dashboard Cite

show abstract

“…Confidence in these studies is increased when findings from brain tissue can be replicated in blood plasma. For example, miR‐323a‐5p and miR‐129‐2‐3p were recently found to be up‐regulated in cortical tissue from patients with refractory epilepsy caused by FCD compared with intracranial hematoma patients, which could be confirmed in blood plasma comparing patients with FCD to healthy controls (Sun et al, ; Che et al, ).…”

Section: Micrornas In Human Epilepsy Disorders and Their Potential Usmentioning

confidence: 90%

MicroRNA‐induced silencing in epilepsy: Opportunities and challenges for clinical application

Tiwari

Peariso

Groß

2017

Developmental Dynamics

View full text Add to dashboard Cite

MicroRNAs are master regulators of gene expression. Single microRNAs influence multiple proteins within diverse molecular pathways and networks. Therefore, changes in levels or activity of microRNAs can have profound effects on cellular function. This makes dysregulated microRNA-induced silencing an attractive potential disease mechanism in complex disorders like epilepsy, where numerous cellular pathways and processes are affected simultaneously. Indeed, several years of research in rodent models have provided strong evidence that acute or recurrent seizures change microRNA expression and function. Moreover, altered microRNA expression has been observed in brain and blood from patients with various epilepsy disorders, such as tuberous sclerosis. MicroRNAs can be easily manipulated using sense or antisense oligonucleotides, opening up opportunities for therapeutic intervention. Here, we summarize studies using these techniques to identify microRNAs that modulate seizure susceptibility, describe protein targets mediating some of these effects, and discuss cellular pathways, for example neuroinflammation, that are controlled by epilepsy-associated microRNAs. We critically assess current gaps in knowledge regarding target-and cell-specificity of microRNAs that have to be addressed before clinical application as therapeutic targets or biomarkers. The recent progress in understanding microRNA function in epilepsy has generated strong momentum to encourage in-depth mechanistic studies to develop microRNA-targeted therapies. Developmental Dynamics 247:94-110, 2018. V C 2017 Wiley Periodicals, Inc.

show abstract

“…Similarly to seizures, traumatic brain injury (TBI) alters miRNA profiles in the brains of rat and mouse models (Lei et al, 2009; Redell et al, 2009; Liu L. et al, 2014). Of note, TBI and epilepsy not only induce changes in the brain, but also lead to altered miRNA content of patient blood serum samples (Redell et al, 2010; Wang et al, 2015; Sun et al, 2016; Che et al, 2017). Therefore, miRNAs have been proposed as biomarkers in both diseases, but their clinical utility is not proven yet (Henshall et al, 2016; Martinez and Peplow, 2017; Tiwari et al, 2018).…”

Section: The Mirna Pathway Is Tightly Regulated In Neuronsmentioning

confidence: 99%

microRNAs Sculpt Neuronal Communication in a Tight Balance That Is Lost in Neurological Disease

Thomas

Groß

Bassell

2018

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Since the discovery of the first microRNA 25 years ago, microRNAs (miRNAs) have emerged as critical regulators of gene expression within the mammalian brain. miRNAs are small non-coding RNAs that direct the RNA induced silencing complex to complementary sites on mRNA targets, leading to translational repression and/or mRNA degradation. Within the brain, intra- and extracellular signaling events tune the levels and activities of miRNAs to suit the needs of individual neurons under changing cellular contexts. Conversely, miRNAs shape neuronal communication by regulating the synthesis of proteins that mediate synaptic transmission and other forms of neuronal signaling. Several miRNAs have been shown to be critical for brain function regulating, for example, enduring forms of synaptic plasticity and dendritic morphology. Deficits in miRNA biogenesis have been linked to neurological deficits in humans, and widespread changes in miRNA levels occur in epilepsy, traumatic brain injury, and in response to less dramatic brain insults in rodent models. Manipulation of certain miRNAs can also alter the representation and progression of some of these disorders in rodent models. Recently, microdeletions encompassing MIR137HG, the host gene which encodes the miRNA miR-137, have been linked to autism and intellectual disability, and genome wide association studies have linked this locus to schizophrenia. Recent studies have demonstrated that miR-137 regulates several forms of synaptic plasticity as well as signaling cascades thought to be aberrant in schizophrenia. Together, these studies suggest a mechanism by which miRNA dysregulation might contribute to psychiatric disease and highlight the power of miRNAs to influence the human brain by sculpting communication between neurons.

show abstract

Expression of microRNA-129-2-3p and microRNA-935 in plasma and brain tissue of human refractory epilepsy

Cited by 33 publications

References 30 publications

Epilepsy biomarkers – Toward etiology and pathology specificity

Epilepsy biomarkers – Toward etiology and pathology specificity

MicroRNA‐induced silencing in epilepsy: Opportunities and challenges for clinical application

microRNAs Sculpt Neuronal Communication in a Tight Balance That Is Lost in Neurological Disease

Contact Info

Product

Resources

About